Banco De Chile (NYSE:BCH – Free Report) had its price objective raised by JPMorgan Chase & Co. from $42.00 to $45.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a neutral rating on the bank’s stock. BCH has been the subject of several other research reports. UBS Group set a […]
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Genpact (NYSE:G) Price Target Raised to $45.00 | 0 | 14.26 | 10-08-2026 |
| 2 | Cadre (NYSE:CDRE) Price Target Raised to $45.00 | 0 | 13.85 | 10-08-2026 |
| 3 | Sotera Health (NASDAQ:SHC) Price Target Raised to $18.00 | 0 | 12.25 | 10-08-2026 |
| 4 | Target (NYSE:TGT) Price Target Raised to $157.00 | 0 | 13.85 | 10-08-2026 |
| 5 | Qiagen (NYSE:QGEN) Price Target Raised to $50.00 | 0 | 14.26 | 10-08-2026 |
| 6 | TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $72.00 | 0 | 13.04 | 10-08-2026 |
| 7 | Chime Financial (NASDAQ:CHYM) Price Target Raised to $33.00 | 0 | 13.43 | 10-08-2026 |
| 8 | Replimune Group (NASDAQ:REPL) Price Target Raised to $20.00 | 0 | 13.83 | 10-08-2026 |
| 9 | HA Sustainable Infrastructure Capital (NYSE:HASI) Price Target Raised to $51.00 | 0 | 13.77 | 10-08-2026 |
| 10 | Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $62.00 | 0 | 13.82 | 10-08-2026 |